| P50 | author | Dennis Ross-Degnan | Q88489251 |
| | Anita K. Wagner | Q124500145 |
| P2093 | author name string | Christine Y Lu | |
| | Jason C Hsu | |
| | Fang Zhang | |
| P2860 | cites work | Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study | Q44051372 |
| | Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th | Q51897454 |
| | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis | Q57618794 |
| | Segmented regression analysis of interrupted time series studies in medication use research | Q74601008 |
| | Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert | Q83723528 |
| | Communicating the risks of medicines: time to move forward | Q84119464 |
| | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007 | Q33327179 |
| | Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 |
| | Changes in glitazone use among office-based physicians in the U.S., 2003-2009. | Q33751542 |
| | Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study | Q33774659 |
| | Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 |
| | Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality | Q34127761 |
| | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 |
| | Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 |
| | Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 |
| | Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis | Q34767965 |
| | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 |
| | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis | Q35382193 |
| | Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review | Q35928690 |
| | Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus | Q36934278 |
| | Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 |
| | Methods for estimating confidence intervals in interrupted time series analyses of health interventions | Q37310071 |
| | Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors | Q37402764 |
| | Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. | Q37643407 |
| | Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study | Q37693536 |
| | Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus | Q37779859 |
| | Rosiglitazone, myocardial ischemic risk, and recent regulatory actions | Q37980720 |
| | Use of interrupted time series analysis in evaluating health care quality improvements | Q38165467 |
| | PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? | Q39740098 |
| | Rosiglitazone and implications for pharmacovigilance | Q42745997 |
| | Responding to an FDA warning--geographic variation in the use of rosiglitazone | Q42806869 |
| | Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration | Q42860408 |
| | Insiders criticise FDA's decision not to withdraw rosiglitazone | Q42873506 |
| | Rosiglitazone: what went wrong? | Q42916313 |
| P433 | issue | 7 | |
| P304 | page(s) | 1420-1432.e1 | |
| P577 | publication date | 2015-05-11 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? | |
| P478 | volume | 37 | |